The overall objective of the study is to determine the therapeutic effect and tolerance of Eculizumab in patients with moderate, severe pneumonia or critical pneumonia associated with Coronavirus disease 2019 (COVID-19). Eculizumab is a terminal complement inhibitor that has been investigated for more than 10 years in numerous complement-mediated diseases. The study has a cohort multiple Randomized Controlled Trials (cmRCT) design. Randomization will occur prior to offering Eculizumab administration to patients enrolled in the CORIMUNO-19 cohort. Eculizumab will be administered to consenting adult patients hospitalized with COVID-19 either diagnosed with moderate or severe pneumonia requiring no mechanical ventilation or critical pneumonia requiring mechanical ventilation. Patients who will chose not to receive Eculizumab will receive standard of care. Outcomes of Eculizumab-treated patients will be compared with outcomes of standard of care-treated patients as well as with outcomes of patients treated with other immune modulators.
Drug: Eculizumab
Intravenous administration as follows:
Induction dosage regimen at 1200 mg on Days 1, 4, 8 then 1200 mg or 900 mg on Day 12 depending on the monitoring of Eculizumab Plasma Level and CH5O and sC5B9 and maintenance doses of 900 mg on Days 15, 18 and 22
Inclusion Criteria:
1. Patients between 18 and 675 years old included in the CORIMUNO-19 cohort
2. Patients belonging to one of the 2 following groups
- Group 1: 60 patients not requiring ICU at admission with moderate and severe
pneumopathy according to the WHO Criteria of severity of COVID pneumopathy,
meeting all of the 2 following criteria:
- Respiratory symptoms with radiological findings of pneumonia
- Severe pneumonia requiring ≥ 5L/min of oxygen to maintain SpO2 >97%
- Group 2: 60 patients requiring ICU based on Criteria of severity of COVID
pneumopathy.
- Respiratory failure and requiring mechanical ventilation
- Vasopressive support
3. Vaccinated against meningococcal infections within 3 years prior to, or at the time
of, initiating Eculizumab to reduce the risk of meningococcal infection (N
meningitidis) [(Bexsero® (2 injections with a minimum of 1 month interval) + Menveo@
or Niminrex® ) and daily antibiotics (Oracilline®)]. If vaccination cannot be
confirmed or if the patient cannot receive it, the participant should receive
prophylactic antibiotics against meningococcal infection prior to initiating
Eculizumab treatment and for at least 3 months from the last infusion of Eculizumab.
4. Female patients of childbearing potential and male patients with female partners of
childbearing potential must follow protocol-specified guidance for avoiding pregnancy
while on treatment and for 8 months after last dose of Eculizumab.
5- Body weight ≥40 kg
6-Patient and/or alternatively by next-of-kin must be willing and able to give written
informed consent according to the applicable regulations including emergency and intensive
care contexts
Exclusion Criteria:
- Patients with exclusion criteria to the CORIMUNO-19 cohort.
- Age ≥ 70 years
- Pregnancy or lactation
- History or unresolved Neisseria meningiditis infection
- Ongoing sepsis, presence or suspicion of active and untreated systemic bacterial
infection prior study screening and untreated with antibiotics,
- Hypersensitivity to any ingredient contained in Eculizumab, including hypersensitivity
to murine proteins.
Saint Louis
Paris, Ile De France, France
Réanimation médicale
Paris, France
saint Louis
Paris, France
Régis Peffault de Latour, MD PhD
1 42 49 96 39 - +33
regis.peffaultdelatour@aphp.fr